Oncology
FDA Told a Promising ADC: Not Yet.
Merck and Daiichi Sankyo have withdrawn their U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer after FDA concluded the Phase II evidence was insufficient. The drug is not dead. The evidentiary shortcut is.
Breast Cancer Gets a New PI3K Pathway Option.
Bladder Cancer Surgery Just Became a System Test
A Blood Test Will Not Fix Colorectal Screening by Itself
Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.
Desmoid Tumours Are Not Benign to the People Living With Them
Pancreatic Cancer Is Forcing Regulators to Move Faster
Ultra-processed food may leave a metabolic fingerprint in the blood.
Medicare Is Coming for the Oncology Margin
Early Lung Cancer Just Became a Biomarker Test of the System
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases